Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01878708 · ClinicalTrials.gov registry record · Early Phase 1
A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma
A Early Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 2
- Enrollment target
NCT01878708 is a Early Phase 1 study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 2 participants.
The verdict
NCT01878708, a Early Phase 1 study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is an open-label, single-arm pilot study of Oncaspar® with dexamethasone for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), excluding extranodal NK/T cell lymphoma (ENKTL). Patients will receive up to 8 courses of treatment.
Interventions
- DRUG Dexamethasone acetate
- DRUG PEG-L-asparaginase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2013-07 |
| Est. Completion | 2017-02 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01878708
The ClinicalTrials.gov registry entry for NCT01878708 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dexamethasone acetate is the first listed.
NCT01878708 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01878708 about?
NCT01878708 is a clinical study titled "A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma". This is an open-label, single-arm pilot study of Oncaspar® with dexamethasone for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), excluding extranodal NK/T cell lymphoma (ENKTL). Patients will receive up to 8 courses of treatment.
What is the current status of trial NCT01878708?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 2 participants. The study started on 2013-07. Estimated completion is 2017-02.
What interventions are being tested in trial NCT01878708?
The interventions under investigation include: Dexamethasone acetate (DRUG), PEG-L-asparaginase (DRUG).
Who is sponsoring clinical trial NCT01878708?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.